Biosimilars are biological agents that are highly analogous to their reference products currently approved and licensed by the U.S. Food and Drug Administration (FDA). Biosimilars possess no differences in their safety, purity, potency, or effectiveness compared to their respective reference biologic agents.
Conclusion: Clinicians can expand their knowledge base and awareness of advances in biosimilars and their use in specialty practices from their respective specialty associations. Additional information can also be attained from the FDA website. The cost-saving potential of biosimilars should be taken into account and analyzed for the best treatment options for the patients.